Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female.

Vaccination for COVID19 infection is in full swing all around the world and while the vaccines are considered overall safe, many cutaneous and extracutaneous adverse effects have been reported after their use. Local injection-site reactions are the commonest adverse effect described with the use of these vaccines. We describe a case of Sweet syndrome in an elderly female after the first dose of Oxford-AstraZeneca COVID-19 vaccine (AZD1222).

Majid I ，Mearaj S 《-》

Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.

Žagar T ，Hlača N ，Brajac I ，Prpić-Massari L ，Peternel S ，Kaštelan M ... -  《-》

Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.

Meo SA ，Fahad Al-Jassir F ，Al-Qahtani S ，Albarrak R ，Usmani AM ，Klonoff DC ... -  《-》

Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.

The AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine is associated with Thrombosis with Thrombocytopenia Syndrome (TTS) in 3/100,000 vaccinations with high fatality rates reported in many countries. We conducted a risk-benefit analysis for Australians aged 18-59 years, comparing the risk of vaccination versus infection, and rate of TTS to other vaccines which prompted policy change following rare adverse events - rotavirus, smallpox and oral polio vaccines. COVID-19 deaths over 12 months range from 0 to 417 in current and future worst case scenarios. In the past 15 months 20 COVID-19 deaths occurred in people < 60 years compared to 890 deaths over 60 years. The estimated possible number of TTS cases is 347, with vaccine-related deaths ranging from 17 to 153if 80% of adults 18-59 years are vaccinated. The reported rate of TTS is in the same range as rare but serious adverse events associated with other vaccines that have been subject to policy change. In Australia, the potential risks of the AZD1222 vaccine in younger adults, who are at low risk of dying from COVID-19, may outweigh the benefits.

MacIntyre CR ，Veness B ，Berger D ，Hamad N ，Bari N ... -  《-》

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.

Cutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized. To describe and classify cutaneous reactions after SARS-CoV-2 vaccination. A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification. From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40·2%), mRNA-1273 (Moderna; 36·3%) and AZD1222 (AstraZeneca; 23·5%) vaccines. Mean patient age was 50·7 years and 80·2% were female. Cutaneous reactions were classified as injection site ('COVID arm', 32·1%), urticaria (14·6%), morbilliform (8·9%), papulovesicular (6·4%), pityriasis rosea-like (4·9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13·8% of reactions. The COVID arm was almost exclusive to women (95·4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61·9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17·2%) and urticaria (AZD1222, AstraZeneca, 21·1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90·5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment. Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.

Català A ，Muñoz-Santos C ，Galván-Casas C ，Roncero Riesco M ，Revilla Nebreda D ，Solá-Truyols A ，Giavedoni P ，Llamas-Velasco M ，González-Cruz C ，Cubiró X ，Ruíz-Villaverde R ，Gómez-Armayones S ，Gil Mateo MP ，Pesqué D ，Marcantonio O ，Fernández-Nieto D ，Romaní J ，Iglesias Pena N ，Carnero Gonzalez L ，Tercedor-Sanchez J ，Carretero G ，Masat-Ticó T ，Rodríguez-Jiménez P ，Gimenez-Arnau AM ，Utrera-Busquets M ，Vargas Laguna E ，Angulo Menéndez AG ，San Juan Lasser E ，Iglesias-Sancho M ，Alonso Naranjo L ，Hiltun I ，Cutillas Marco E ，Polimon Olabarrieta I ，Marinero Escobedo S ，García-Navarro X ，Calderón Gutiérrez MJ ，Baeza-Hernández G ，Bou Camps L ，Toledo-Pastrana T ，Guilabert A ... -  《-》